Yarina 21 tablets — Made in Germany — Free Delivery

Product description

Yarina® tablets are used for oral contraception.

Structure

One film-coated tablet contains (active ingredients):

• ethinylestradiol - 0.03 mg;
• drospirenone - 3 mg.

Excipients: lactose monohydrate, corn starch, pregelatinized corn starch, povidone, magnesium stearate, hydroxypropyl methylcellulose, macrogol 6000, talc, titanium dioxide (E 171), iron oxide yellow (E 172).

Contraindications

Combined hormonal contraceptives (CHCs) should not be used if at least one of the following conditions is present. If any of these conditions occurs for the first time during the use of CHC, the drug should be stopped immediately.

The presence or risk of developing venous thromboembolism (VTE):

• VTE at present, in particular due to anticoagulant therapy or a history (for example, deep vein thrombosis (DVT) or pulmonary embolism (PE));
• known hereditary or acquired tendency to VTE, such as resistance to activated protein C (including factor V Leiden mutation), antithrombin-III deficiency, protein C deficiency, protein S deficiency;
• large surgical interventions with prolonged immobilization;
• high risk of VTE due to the presence of multiple risk factors.

Presence or risk of developing arterial thromboembolism (ATE):

• current or history of ATE (eg myocardial infarction) or the presence of prodromal symptoms (eg angina pectoris);
• current or history of cerebrovascular accident, prodromal symptoms (eg, transient ischemic attack (TIA));
• a known hereditary or acquired tendency towards ATUs such as hyperhomocysteinemia and antibodies to phospholipids (eg antibodies to cardiolipins, lupus anticoagulant);
• migraine with a history of focal neurological symptoms;

high risk of ATE due to the presence of multiple risk factors or due to the presence of one serious risk factor, such as:

• diabetes mellitus with vascular complications;
• severe arterial hypertension;
• severe dyslipoproteinemia.

Present or history of severe liver disease before liver function tests return to normal.

Severe renal failure or acute renal failure.

Current or history of liver tumors (benign or malignant).

Known or suspected malignant tumors (eg, genitals or mammary glands) that are sex hormone dependent.

Vaginal bleeding of unknown etiology.

Hypersensitivity to active substances or to any of the components of the drug.

Suspected or confirmed pregnancy.

The drug "Yarina®" is contraindicated when used simultaneously with drugs containing ombitasvir / paritaprevir / ritonavir and dasabuvir.

Mode of application

Orally. The tablets should be taken regularly at about the same time, with a small amount of liquid if necessary, in the order indicated on the package. The drug is taken one tablet per day for 21 consecutive days. Taking pills from each subsequent package should be started after the end of the 7-day break in taking the drug, during which withdrawal bleeding usually occurs. As a rule, it starts on the 2-3rd day after taking the last pill and may not end before taking the pills from the next pack.

Application features

Children

The drug "Yarina®" is indicated for use only after the onset of the first menstruation. Based on epidemiological data collected from more than 2,000 adolescents under the age of 18, there is no data showing a difference in the safety and efficacy of this group of patients compared with women aged 18 and over.

Drivers

No studies have been conducted on the effect on the ability to drive vehicles or operate other mechanisms. In women taking combined oral contraceptives, no effect on the ability to drive vehicles or operate other mechanisms was reported.

Overdose

Until now, there are no data of clinical studies regarding an overdose of tablets of the drug "Yarina®". As general experience with COCs shows, overdose may result in nausea, vomiting and withdrawal bleeding. Withdrawal bleeding can be observed in girls even before the onset of menarche in case of unintentional / accidental use of the drug. There is no specific antidote; treatment must be symptomatic.

Side effects

Below are the side reactions that were observed with the use of the drug "Yarina" most often (≥ 1/100 and <1/10).

Mental disorders: depressed mood.

From the nervous system: headache.

From the side of the vessels: migraine.

From the gastrointestinal tract: nausea.

From the reproductive system and mammary glands: menstrual disorders, intermenstrual bleeding, breast tenderness, engorgement of the mammary glands, vaginal discharge, vulvovaginal candidiasis.

Storage conditions

Store at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 3 years.